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Abstract
Purpose To determine which health care provider and what timing is considered most suitable to discuss sexual and relational
changes after prostate cancer treatment according to the point of view of men and their partners.
Methods A cross-sectional survey was conducted among men diagnosed with prostate cancer or treated after active
surveillance, who received laparoscopic radical prostatectomy, brachytherapy, intensity-modulated radiotherapy, and/
or hormonal therapy. If applicable, partners were included as well.
Results In this survey, 253 men and 174 partners participated. Mean age of participating men was 69.3 years (SD
6.9, range 45–89). The majority (77.8%) was married and average length of relationship was 40.3 years (SD 14.1,
range 2–64). Out of 250 men, 80.5% suffered from moderate to severe erectile dysfunction. Half of them (50.2%,
n = 101) was treated for erectile dysfunction and great part was partially (30.7%, n = 31) up to not satisfied (25.7%,
n = 26). Half of the partners (50.6%, n = 81) found it difficult to cope with sexual changes. A standard consultation
with a urologist-sexologist to discuss altered sexuality is considered preferable by 74.7% (n = 183). Three months
after treatment was the most suitable timing according to 47.6% (n = 49).
Conclusions During follow-up consultations, little attention is paid to the impact of treatment-induced sexual dys-
function on the relationship of men with prostate cancer and their partners. A standard consultation with a urologist-
sexologist 3 months after treatment to discuss sexual and relational issues is considered as most preferable.
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Background
Prostate cancer (PCa) is the most common cancer among men
in the Western world, with approximately 11.000 cases diag-
nosed in the Netherlands each year [1]. Increased public
awareness and prostate-specific antigen testing partially ex-
plain the raise of PCa detection [2]. Treatment method is pri-
marily selected according to disease stage and where applica-
ble, to the patient’s preference. Early detection and improve-
ment of therapies have led to an increase in survival outcomes,
meaning PCa therapy may be curative or life prolonging.
Nevertheless, can PCa treatment affect quality of life (QoL)
majorly [3]. Among other treatment-related side effects, such
as incontinence of urine, sexual dysfunction (SD) is one of the
most prevalent consequences of PCa treatment with erectile
dysfunction (ED) as primary complaint [4]. Five years after
* Lorena A. Grondhuis Palacios
L.A.Grondhuis_Palacios@lumc.nl
1 Department of Urology, Leiden University Medical Center, PO Box
9600, 2300 WB Leiden, The Netherlands
2 Department of Medical and Clinical Psychology, Tilburg University,
PO Box 90153, 5000 LE Tilburg, The Netherlands
3 Research Center of Nursing, Saxion University of Applied Sciences,
PO Box 70000, 7500 KB Enschede, The Netherlands
4 Department of Psychology, Education & Child Studies, Erasmus
University Rotterdam, PO Box 1738, 3000
DR Rotterdam, The Netherlands
5 Department of Medical Statistics, Leiden University Medical Center,
PO Box 9600, 2300 WB Leiden, The Netherlands
Supportive Care in Cancer
https://doi.org/10.1007/s00520-018-4290-2
diagnosis, 79% of men treated with radical prostatectomy
(RP) experience ED and 64% of men treated with radiothera-
py [5]. Seventy-two percent of men treated with RP experi-
ence significant loss of QoL due to ED [6]. At present, com-
mon ED treatment options consist of PDE5 inhibitors, intra-
urethral medications, intracavernous injections, vacuum ther-
apy and penile protheses [7]. Despite PDE5 inhibitors are
considered as first-line treatment, alprostadil or tadalafil in
comparison to placebo does not always show significant im-
provement in RP-related ED [8, 9]. Accordingly, it is impor-
tant to initiate penile rehabilitation after PCa treatment as soon
as possible in order to encounter which treatment suits best.
Alterations in sexual health do not only affect men, but
their partners as well. Partners report higher levels of anx-
iety, not only as a result of coping with the disease, but
also due to changes in their sexual relationship [10].
Thirty-eight percent stated to be unsatisfied with the sex-
ual relationship with their partner [11]. Moreover, changes
in a sexual relationship can negatively affect the overall
relationship [12]. A study performed among couples fac-
ing PCa showed that both men and partners suffered from
the impact of the treatment-related side effects on their
psychological wellbeing as well as on their romantic rela-
tionship [13].
Nevertheless, limited research has been performed to in-
vestigate adequate management of sexual side effects of PCa
treatment [14]. There are limited opportunities for men and
partners to address the impact of the treatment-related side
effects on their sexual health during follow-up consultations,
since priority is given to disease control [15]. Consequently,
psychological wellbeing of men and their partners may be
impaired, leading to a decrease in QoL [16].
Hence, we aimed to evaluate the current situation of sexual
health care and satisfaction of treatment options provided to
men experiencing treatment-related SD. Furthermore, we
aimed to investigate which health care provider is preferred
and what timing is considered as most suitable for sexual
counseling after PCa treatment according to the point of view
of men and their partners.
Methods
Study population
For this cross-sectional study, patients were recruited
throughout the oncology regis t ra t ion of Leiden
University Medical Center. Based on the hospital’s decla-
ration code for PCa, a list was obtained with patients
diagnosed with or treated for PCa between 2013 and
2015. Subsequently, the list also comprised patients who
were diagnosed with or treated for PCa before 2013 and
had received an (additional) treatment between 2013 and
2015. Patients under active surveillance (AS) or treated
(after AS) with laparoscopic radical prostatectomy
(LRP), brachytherapy (BT), intensity-modulated radio-
therapy (IMRT) and/or hormonal therapy (HT) were in-
cluded. Additional patient data obtained from the oncolo-
gy registration included age, PCa staging and type of ob-
tained treatment(s). Using the registration of the munici-
pal personal records database, patients who deceased or
moved abroad were refined. This process led to a total of
590 eligible men. In June 2015, an information letter and
a consent form for patient and/or their partner were sent
by mail. Reason to not participate, could be indicated on
the consent form. With affirmative consent, questionnaires
were sent in separate, post-paid envelopes to warranty
privacy of patients and their partners.
Materials: questionnaire design
The questionnaires were designed by the authors, based on the
study aim and review of literature. The questionnaire devel-
oped for patients treated after diagnosis or after AS, consisted
of 47 items assessing topics such as socio-demographic fac-
tors, sexual function (SF) before and after treatment, experi-
ence and satisfaction regarding current sexual health care and
desired sexual health management. A similar questionnaire
was developed for patients who were under AS where ques-
tions around received treatment were withdrawn. The ques-
tionnaire developed for partners consisted of 14 items includ-
ing socio-demographic factors, sexuality throughout their
partner’s treatment and whether counseling in sexuality and/
or relational matters would be appreciated.
In February 2015, a pilot test was performed among five
members of the Dutch PCa Foundation to improve suitability
and comprehensiveness of the questionnaire. Adjustments
were made to the content, phrasing of questions and additions
to answer possibilities were performed. Due to an incorrect
question-answer combination with regard to the question what
timing was found to be suitable for sexual counseling, part of
the answers lapsed. Responses from the participants who had
interpreted the question correctly, were described in the
results.
Statistical analysis
Quantitative data were analyzed using IBM SPSS Statistics,
version 23.0. Descriptive statistics were used to analyze de-
mographic and clinical variables. Numerical variables were
described with mean (SD), categorical variables with number
(%). Associations between preferred health care provider and
clinical data were analyzed using the Pearson’s Chi-Square
test. Associations in clinical data were calculated using the
McNemar test. Two-sided p values < 0.05 were considered
statistically significant.
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Ethics
The protocol for this study was approved by the Institutional
Review Board at Leiden University Medical Center in June
2015. Consent was essential, since it concerned a survey with
sensitive questions and confidentiality of the participants had
to be guaranteed.
Results
A total of 584 men were eligible to participate in this study (in
hindsight six men were considered ineligible to participate,
due to death after start of the study). Among men who did
not want to participate in the study (n = 168), most named
reasons were non-interest (n = 49), irrelevance regarding im-
provement in this area (n = 33) and questions being too per-
sonal (n = 29). A remaining group of 134 men who were
approached, did not respond throughout the consent form. A
group of 29 men gave their consent, yet did not return the
questionnaire. Consequently, a total of 253 men participated
in our study.
Socio-demographic characteristics
The average age of men was 69.3 years (SD 6.9, range 45–
89), the majority (78.6%, n = 198) was retired. Almost 78.0%
(n = 196) was married, with an average duration of the rela-
tionship of 40.3 years (SD 14.1, range 2–64). PCa was diag-
nosed at an average age of 66.2 years (SD 6.7, range 42–86)
and most participants (91.7%, n = 232) had localized disease
at the time of diagnosis. IMRT combined with HT was the
most common type of treatment received (28.1%, n = 71),
followed by LRP (25.3%, n = 64) and IMRT (23.7%, n =
60). Further details on demographic and clinical characteris-
tics are shown in Table 1.
Sexual function throughout treatment
Prior to treatment, 34.6% out of 250 participating men
had moderate to severe ED. After treatment a significant
difference in ED was found: 80.5% suffered from moder-
ate to severe treatment-related ED (p < 0.001). Half of the
participants (50.0%, n = 124) was no longer sexually ac-
tive due to treatment and 78.2% (n = 190) reported dete-
riorated SF. Erectile complaints were experienced imme-
diately after treatment mostly by men treated with LRP
(93.8%, n = 60) followed by men treated with IMRT com-
bined with HT (77.9%, n = 53). In Table 2, presence of
ED before and after treatment is displayed for the differ-
ent types of treatment, with the greatest increase of per-
centage points in men treated with LRP and in men
treated with IMRT combined with HT by 62.5% (p <
0.001) and 53.3% (p < 0.001) respectively.
Table 1 Demographic and clinical characteristics of participating men
n (%)
Age (years)
Mean 69.3 (SD 6.9, range 45–89) 253 (100.0)
Occupation
Employed 47 (18.6)
Unemployed 7 (2.8)
Retired, employed 69 (27.3)
Retired, unemployed 129 (50.9)
Unknown 1 (0.4)
Education
No qualification/elementary school 16 (6.3)
Lower vocational education 65 (25.7)
Intermediate vocational education 56 (22.1)
Higher secondary education 33 (13.1)
Higher education 81 (32.0)
Unknown 2 (0.8)
Marital status
Unmarried 18 (7.1)
Married 196 (77.5)
Common law 11 (4.3)
Widowed 13 (5.1)
Other 14 (5.5)
Unknown 1 (0.5)
Duration of relationship (years)
Mean 40.3 (SD 14.1, range 2–64) 217 (85.8)
Age at diagnosis (years)
Mean 66.2 years (SD 6.7, range 42–86) 253 (100)
TNM staging
T—localized disease 232 (91.7)
N—regional lymph node metastases 11 (4.3)
M—metastasized disease 8 (3.2)
TNM staging unknowna 2 (0.8)
Type of treatment
Active surveillance (AS) 17 (6.7)
Laparoscopic radical prostatectomy (LRP)b 64 (25.3)
Brachytherapy (BT) 25 (9.9)
Intensity-modulated radiotherapy (IMRT) 60 (23.7)
IMRT combined with HTc 71 (28.1)
Hormonal therapy (HT) 15 (5.9)
Otherd 1 (0.4)
a Clinical diagnosis, no TNM staging available
b Including LRP combined with IMRT (n = 5) and LRP combined with
HT (n = 1)
c Including BTcombined with HT (n = 8) and IMRTcombined with LRP
and HT (n = 4)
d Pelvic lymph node dissection (n = 1)
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ED treatment options
Participants were asked to report which types of ED treatment
options were offered by their health care provider. Out of
available ED treatment options, PDE5 inhibitors were offered
the most (50.0%, n = 94), followed by a single consultation to
discuss sexual health (12.8%, n = 24), intra-urethral medica-
tions (11.2%, n = 21), intracavernosal injections (6.9%, n =
13), and vacuum therapy (5.4%, n = 10). One out of seven
men (14.4%, n = 27) indicated their health provider never of-
fered an ED treatment option. Out of 101 men, a third indi-
cated Bpartial satisfaction^ (30.7%) up to Bno satisfaction^
(25.7%) regarding treatment for their erectile complaints.
Reasons for dissatisfaction consisted of limited results
(54.8%, n = 17), discomfort (6.5%, n = 2), and high costs
(3.2%, n = 1). Six participants (19.4%) indicated to be unable
to report results concerning the effect of ED treatment, as they
had not used the prescribed medication yet. Despite preceding
results, only a third of men with ED (31.2%, n = 58) were
offered the possibility to discuss sexuality with a specialized
health care provider, such as a sexologist.
Partners
A total of 174 partners of men with PCa participated in this
study, among them 171 women and 3 men. The average age
was 65.5 years (SD 7.6, range 45–86) and the majority
(65.6%, n = 114) was retired. Further details on demographic
and clinical characteristics are shown in Table 3.
Half of the partners (50.6%, n = 81) reported to have expe-
rienced difficulties handling the altered situation regarding
sexuality. Fifty-one percent (n = 85) reported to have faced
moderate to severe problems concerning sexuality subsequent
to treatment of their partner. As regards to other treatment-
related side effects, such as urinary incontinence, 61.6%
(n = 101) mentioned to have not experienced difficulties deal-
ing with it. Nevertheless, the majority of the partners (69.3%,
n = 115) mentioned these changes in intimacy have not influ-
enced their romantic relationship.
Regardless the fact that almost half of the partners reported
difficulties around sexuality with their partner, 86.9% (n = 93)
indicated to not be in need of additional support for sexual
health and/or relational issues. A few partners (11.5%, n = 6)
indicated that a long-term relationship should be capable of
overcoming these kind of obstacles, and although a sexual
relationship is no longer existent, being intimate in another
way is considered satisfactory as well. Several partners
(25.0%, n = 13) reported to have accepted the new situation
around sexuality and experienced improved communication
within their relationship due to this alteration. Still, a greater
part of the partners (29.8%, n = 36), who did not feel the
necessity to obtain additional support, reported to have expe-
rienced difficulties with their sexuality and relationship. Lack
of intimacy (33.3%, n = 12), loss of their sexual relationship
(27.8%, n = 10), coping with frustrations of their partner, and
coming from dealing with ED as well as the feeling of loss of
masculinity (25.0%, n = 9) and increased tension in their rela-
tionship (13.9%, n = 5) were the most named reasons.
Preferred sexual health care
We asked the participants whether they would appreciate it to
discuss treatment-related SD and relational matters with cer-
tain health care providers. On the assumption this would take
place with a urologist-sexologist, the majority (74.7%, n =
183) answered positively. In case that would concern a sexol-
ogist, 43.0% (n = 104) agreed and if these subjects would be
discussed with an oncology nurse, 40.5% (n = 98) conceded.
Around one fourth of participating men (24.4%, n = 60) indi-
cated such a consultation should only occur on patients’ ini-
tiative. Two men preferred to discuss these personal matters
with their general practitioner.
Preferences for certain health care providers depending
on received type of treatment were analyzed (see Fig. 1).
Table 2 Moderate to severe ED before and after treatment
ED prior to treatment n (%) ED after treatment n (%) Percent difference (%) p valuec
Type of treatment
Active surveillance (AS) 5 (29.4) 6 (35.3) 5.9 NS (1.000)
Laparoscopic radical prostatectomy (LRP)a 20 (31.3) 60 (93.8) 62.5 < 0.001
Brachytherapy (BT) 14 (56.0) 22 (88.0) 32.0 0.021
Intensity-modulated radiotherapy (IMRT) 26 (43.3) 47 (81.0) 37.7 < 0.001
IMRT combined with HTb 17 (24.6) 53 (77.9) 53.3 < 0.001
Hormonal therapy (HT) 5 (33.3) 11 (73.3) 40.0 NS (0.070)
NS not significant
a Including LRP combined with IMRT (n = 5) and LRP combined with HT (n = 1)
b Including BT combined with HT (n = 8) and IMRT combined with LRP and HT (n = 4)
cMcNemar test
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Out of all men who preferred the urologist-sexologist, this
health care provider was named the most by men who had
undergone surgical treatment (84.4%, n = 54). When compar-
ing the group by whom the urologist-sexologist was named
the least, namely men who received IMRTcombined with HT
(64.7%, n = 64), a significant difference was found (p = 0.01).
Again, the group of men who received IMRT combined with
HT was in the minority as to when the sexologist was
suggested as a suited health care provider (27.3%, n = 19).
When comparing the group of men treated with IMRT com-
bined with HT with the LRP treatment group as well as with
all other types of treatments, a significant difference in pref-
erence as to the sexologist as most suited health care provider
was found (p < 0.05 and p < 0.05). With regard to the prefer-
ence for the oncology nurse, no significant difference was
found when the group of men who received IMRT was com-
pared to the HT treatment group nor to all other types of
treatments (p = 0.38 and p = 0.34).
Subsequently, participants were inquired to determine the
most suitable timing for sexual counseling. Almost half of the
participants (47.6%, n = 49) considered 3 months after treat-
ment as best suited. A third (33.0%, n = 34) preferred as soon
as possible; meaning the first visit attending their urologist;
around 4 weeks after treatment. A minority (11.6%, n = 12)
mentioned a period of 6 to 9 months after treatment as conve-
nient, followed by a group who considered 1 year after treat-
ment as most suited (7.8%, n = 8).
As to which extent involvement of partners is important
when sexuality is discussed, 67.9% (n = 144) of participating
men determined involvement of their partner as crucial. A
small part (20.3%, n = 43) indicated to not feel concerned
whether their partner is involved or not and 11.8% (n = 25)
preferred to discuss intimate issues without the presence of
their partner.
Discussion
Key results
This study shows current sexual health care is not conclusive
according to men experiencing SD due to PCa treatment.
Significant loss of erectile function (EF) is experienced by
the majority of men treated for PCa. Several ED treatment
options are available, for what PDE5 inhibitors were
Table 3 Demographic and clinical characteristics of the partners
n (%)
Age (years)
Mean 65.5 (SD 7.5, range 45–86) 174 (100.0)
Gender
Female 171 (98.3)
Male 3 (1.7)
Occupation
Employed 46 (26.4)
Unemployed 14 (8.1)
Retired, employed 19 (10.9)
Retired, unemployed 95 (54.6)
Education
No qualification/elementary school 12 (6.9)
Lower vocational education 79 (45.4)
Intermediate vocational education 33 (19.0)
Higher secondary education 17 (9.7)
Higher education 33 (19.0)
Marital statusa
Unmarried 4 (2.3)
Married 146 (83.9)
Common law 7 (4.0)
Widowed 1 (0.6)
Other 4 (2.3)
Unknownb 12 (6.9)
Comorbiditiesc
Hypertension 54 (18.4)
Hypercholesterolemia 45 (15.3)
Rheumatic and joints disease 45 (15.3)
Obesity 20 (6.8)
Chronic inflammatory lung disease 16 (5.4)
Diabetes mellitus 15 (5.1)
Psychological disease 13 (4.4)
Heart and coronary artery disease 9 (3.1)
Thyroid disease 7 (2.4)
Cerebrovascular accident 5 (1.7)
Other 15 (5.1)
No comorbidities 50 (17.0)
a Data obtained by correlating partners with corresponding patients
b Partners of patients who did not participate
c Comorbidities are displayed in number of frequencies
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prescribed the most. However, more than half of the partici-
pants were not satisfied with the ED treatment results. A stan-
dard consultation with a urologist-sexologist 3 months after
treatment is preferred by the majority of the participants. The
same consultation performed by a sexologist or an oncology
nurse is considered preferable as well. Men who have received
surgical treatment have a preference for a urologist-sexologist
compared to men who have received IMRT combined with
HT, whom prefer a urologist-sexologist the least. When it
comes to a consultation with a sexologist, the group of men
treated with IMRTcombined with HT preferred the sexologist
the least, whereas the group of men who were treated with
IMRT preferred the sexologist the most. When the consulta-
tion would take place with an oncology nurse, among all types
of treatments, no significant difference was found. Regarding
the partners, half of them encountered issues concerning al-
tered sexuality. However, dealing with other treatment-related
side effects, such as urinary incontinence, were not experi-
enced as a problem by a great number of partners.
Moreover, the majority of the participating men indicated
presence of their partner as crucial during such consultations,
whilst a minority stated to prefer consultations in a private
setting.
Comparison with literature
Although an overall high satisfaction is found concerning
supportive care after treatment, men treated for PCa report-
ed that physical problems are addressed more often than
psychosocial-related issues [4]. SD as a result of PCa treat-
ment comprises several components, including ED.
Gandaglia et al. investigated whether penile rehabilitation
is effective after nerve-sparing RP [17]. Penile rehabilita-
tion was defined in this study as implementation of any
intervention in the context of obtaining erections sufficient
for sexual intercourse, and preferably to obtain EF back to
its preoperative state. Clinical studies reported inconsistent
results as to long-term effects on EF. The authors conclud-
ed that an optimal recovery program for men treated with
RP is still a subject in need of further investigation.
Regarding SF subsequent to RT, Incrocci performed a
study to investigate post-radiation ED in men treated for
PCa [18]. The investigators stated post-radiation ED is a
multi-factorial problem. Consequently, PDE5 inhibitors
seem to be efficacious in only half of men treated with
radiation therapy. In consonance with our study, men who
used PDE5 inhibitors reported dissatisfaction due to lack
of efficacy, high costs and side effects.
Importance of psychosexual care
CurrentWestern health care has gainedmore focus on improv-
ing QoL throughout enhanced disease management,
especially in oncology treatments, considering its great impact
to psychological health and wellbeing [19]. Nevertheless, psy-
chosexual care is still found to be a great unmet need among
the majority of men treated for PCa, since psychosocial and
relational problems are unaddressed in comparison to physical
problems [4]. Despite the fact sexual health issues may con-
cern an important topic to them, they experience difficulties in
disclosing their complaints with health care providers or their
partners [20]. Moreover, many tools are available to provide
proper guidance to men experiencing SD; however, great part
of them are hardly ever used [21].
Noteworthy to mention is the lack of need of the partners to
obtain supportive care around sexuality and/or relational is-
sues. Despite the imposing difference between the two gen-
ders, it has been described in the literature previously [11].
This study described a group of men and their partners where,
comparable to our study group, men were more interested to
obtain supportive care around altered sexuality whereas al-
most half of the partners reported to not be interested in re-
ceiving support for changes in their intimate relationship.
Several types of reasons therefore were named by partners
within our study group. Part of them considered these issues
as an obstacle apparent to overcome within their long-term
relationship, whilst others accepted the altered situation and
even encountered improved communication with their partner.
However, an important number of partners experienced sev-
eral sexual issues, and are still not in need of additional sup-
port. Wittmann et al. studied partners of men surgically treated
for PCa and found that several partners did not attempt to
initiate sexual activities in order to not pressure their partner
to perform [22]. Although partners may experience high un-
met sexual needs, they tend to emphasize other elements of the
relationship rather than the sexual part to not let their partners
feel insecure about their sexual performance [23]. Thereupon,
men reported to be unaware of their partners’ sexual needs. So
despite the fact that partners report to not be in need of sexual
support, they may not be neglected when sexual recovery for
men treated for PCa is considered, since they may disguise
their own sexual needs to prevail upon their partner’s anxiety.
Strengths and limitations
One of the strengths of this study consists of its large cohort of
men obtained from an academical cancer registry center, em-
phasizing the use of accurate and reliable data. Throughout
this study, we were able to identify the unmet needs of men
treated for PCa and to determine their preference by means of
their received treatment. Moreover, we were able to address
the supportive care needs of their partners as well.
Limitations include the cross-sectional research design,
which implies participants presented their experiences retro-
spectively. Longitudinal evaluation of intervention outcomes
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designed according to received treatment and the patient’s
preference are key focus for future research.
Clinical implications
We were able to inventory to what extent ED treatment op-
tions were offered within our department and to which degree
men were satisfied. Based on the study results, a patient-
specific intervention can be developed and implemented.
The outcomes showed that men have the preference to discuss
sexual health issues with a urologist-sexologist the most,
followed by a sexologist and an oncology nurse. Within the
groups of men who received various treatments, preferences
concerning the adequate health care provider differed.
Accordingly, the person who will discuss sexual matters with
men and their partners can be correlated throughout the re-
ceived treatment. Content of these consultations can vary from
discussing altered sexuality, methods as in how to experience
intimacy in a different way to specific sexual education, and
therapy interventions, based on the level of treatment-related
SD and the patient’s and his partner’s preference. It is recom-
mended to implement this standard consultation 3 months af-
ter treatment. The intervention will not only provide the nec-
essary space for men to mention their sexual complaints, in
addition, it will aid to improve the physician-patient relation-
ship as well, enhancing health-related QoL [24]. If the health
care department is unable to provide such consultations with
the suggested health care provider, it becomes fundamental to
identify sexual and/or relational problems in good time so
referral can take place properly. Accordingly, referral systems
within corresponding hospital or clinic should be well-
established.
Conclusions
PCa treatment has important consequences for the psychosex-
ual health and for the relationship between men and their
partners. Unfortunately, it has become an underexposed aspect
during follow-up consultations, leading to a decrease in QoL.
PDE5 inhibitors are considered as the most common ED treat-
ment option, although unsatisfactory results are reported. A
great number of men would rather obtain supportive care pro-
vided by a urologist-sexologist with regard to sexual health
issues and relational matters. Three months after treatment is
considered the most suitable timing. In addition, the majority
prefers their partner to be present during these consultations. It
is therefore recommended to schedule an additional consulta-
tion or to refer a patient to a urologist-sexologist in case altered
sexuality is experienced as a result of PCa treatment.
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